Dual antiplatelet treatment in TIA and high-risk ischemic CVA, a review of the POINT trial

Affiliations

Comment

Margaret Hull. CJEM. 2020 Jan.

. 2020 Jan;22(1):29-30.

doi: 10.1017/cem.2019.407.

No abstract available

Keywords: Drugs and pharmacology; emergency medicine; neurology; stroke/TIA.

Comment on

Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design.
Johnston SC, Easton JD, Farrant M, Barsan W, Battenhouse H, Conwit R, Dillon C, Elm J, Lindblad A, Morgenstern L, Poisson SN, Palesch Y. Johnston SC, et al. Int J Stroke. 2013 Aug;8(6):479-83. doi: 10.1111/ijs.12129. Int J Stroke. 2013. PMID: 23879752 Free PMC article. Clinical Trial.
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, Kim AS, Lindblad AS, Palesch YY; Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators. Johnston SC, et al. N Engl J Med. 2018 Jul 19;379(3):215-225. doi: 10.1056/NEJMoa1800410. Epub 2018 May 16. N Engl J Med. 2018. PMID: 29766750 Free PMC article. Clinical Trial.